# Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

> **NCT02833948** · PHASE3 · COMPLETED · sponsor: **ECRI bv** · enrollment: 231 (actual)

## Conditions studied

- Aortic Valve Stenosis
- Cardiovascular Diseases
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Thrombosis

## Interventions

- **DRUG:** Acetylsalicylic acid
- **DRUG:** Clopidogrel
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT02833948
- **Lead sponsor:** ECRI bv
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2018-12
- **Final completion:** 2019-03-06
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02833948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02833948, "Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02833948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*